Hematologic Oncology

Researchers have observed that HSC–derived innate lymphoid cells prevent GVHD by inducing interleukin 9 driven T-cell senescence.

Researchers have demonstrated that a tandem CAR T cell targeting mesothelin and MUC16 ectodomain is able to outmaneuver tumor heterogeneity, outperforming single target CAR T cells in mixed ovarian and pancreatic models.

Researchers have determined that donor age has a stronger, nonlinear impact on OS vs donor type in allogeneic HCT using posttransplant cyclophosphamide for GVHD prophylaxis, with donor type becoming increasingly relevant in older donors.

Exa-cel displayed MCID-exceeding, sustained mean changes from baseline across various HRQOL-related scores in transfusion-dependent β-thalassemia.

Two hematologic oncologists defined rare lymphomas and highlighted challenges and recent developments associated with these disease types.

The regulatory agency gave a PDUFA target action date of April 6, 2026, for Orca-T among patients with AML, ALL, and MDS.

A study by the Blood and Marrow Transplant Clinical Trials Network found that a donor search prognosis strategy may move those with cancer to HCT faster.

Data from the CADENZA trial support the application for pivekimab sunirine as a treatment for those with blastic plasmacytoid dendritic cell neoplasms.

According to Francesca Palandri, MD, PhD, ruxolitinib will have a less significant effect in patients with myelofibrosis who have a cytopenic phenotype.

Data from a propensity-matched analysis showed that GLP-1 receptor agonists conferred benefits even among patients with type 2 diabetes.

Researchers from the BMT CTN reported that posttransplant cyclophosphamide-based GVHD prophylaxis significantly improves outcomes for adults aged 70 years and older undergoing allo-HCT.

Researchers at the CHOP have developed a new strategy to improve the effectiveness of GPC2-directed CAR T-cell therapy in neuroblastoma by reprogramming the tumor immune microenvironment.

The overall pain experience among adult and pediatric patients with severe sickle cell disease significantly improved after exa-cel infusion.

Results from the phase 3 VERIFY trial of rusfertide for erythrocytosis in patients with polycythemia vera led to the FDA decision.

The 2025 National ICE-T Symposium gave oncology experts an opportunity to share ideas regarding the administration of cellular therapies.

Researchers have found that donor age is a key determinant of outcomes in hematopoietic cell transplantation, with younger donors associated with significantly better survival and lower rates of GVHD.

Following the lifting of a clinical hold, the FDA has again accepted the BLA for tabelecleucel in adult and pediatric patients with EBV-positive PTLD.

Ibrutinib tablets will become available at 140 mg, 280 mg, and 420 mg for patients with chronic lymphocytic leukemia and Waldenström macroglobulinemia.

Many patients reported social/financial vulnerabilities that possibly precluded them from transplant access outside of the phase 2 clinical trial.

The FDA has asked tambiciclib’s developer to start a trial investigating the combination in front-line acute myeloid leukemia.

The FDA lifted a clinical hold on a new drug application for tabelecleucel as a treatment for EBV-positive lymphoproliferative disease in May 2025.

The MALT1 inhibitor demonstrated a favorable safety profile and tolerability in findings from a phase 1 clinical trial presented at the EHA 2025 Congress.

Administering precision-selected donor regulatory T-cell therapy significantly improves GVHD-free, relapse-free survival in patients undergoing allogeneic HCT.

Among 77 enrolled patients, the cumulative incidence of grades 2 to 4 aGVHD at day 100 post-transplantation was 18.2% (95% CI, 10.6–27.6%).

BGB-16673 antitumor activity occurred particularly among patients with BTK-resistant mutations and those with disease refractory to prior cBTK and ncBTK inhibition.